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The outcomes of patients developing major bleeding while on oralanticoagulants remain largely unquantified. The objectives of thisstudy were to: (i) describe the burden of major hemorrhage asso-
ciated with all available oral anticoagulants in terms of proportion of
bleeds which are intracranial hemorrhages, in-hospital mortality and
duration of hospitalization following major bleeding; (ii) identify risk
factors for mortality; and (iii) compare the characteristics of major hem-
orrhage between cases treated with warfarin and direct oral anticoagu-
lants for the subgroups of patients with atrial fibrillation or venous
thromboembolism. This was a multicenter, 3-year prospective cohort
study of patients aged ≥18 years on oral anticoagulants who developed
major hemorrhage leading to hospitalization. The patients were fol-
lowed up for 30 days or until discharge or death, whichever occurred
first. In total 2,192 patients (47% female, 81% on warfarin, median age
80 years) were reported between October 2013 and August 2016 from
32 hospitals in the UK. Bleeding sites were intracranial (44%), gastroin-
testinal (33%), and other (24%). The in-hospital mortality was 21%
(95% CI: 19%-23%) overall, and 33% (95% CI: 30%-36%) for patients
with intracranial hemorrhage. Intracranial hemorrhage, advanced age,
spontaneous bleeding, liver failure and cancer were risk factors for death.
Compared to warfarin-treated patients, patients treated with direct oral
anticoagulants were older and had lower odds of subdural/epidural, sub-
arachnoid and intracerebral bleeding. The mortality rate due to major
bleeding was not different between patients being treated with warfarin
or direct oral anticoagulants. Major bleeding while on oral anticoagulant
therapy leads to considerable hospital stays and short-term mortality. 
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ABSTRACT
Introduction
Oral anticoagulants (OAC) are highly effective for stroke prevention in patients
with atrial fibrillation,1,2 for the treatment and prevention of venous thromboem-
bolism,3 and for the prevention of thrombosis related to mechanical heart valves.4,5
It is estimated that OAC therapy is required for 1.25 million people per year in the
UK with approximately 70% being for those with atrial fibrillation.6 This require-
ment is likely to continue to rise in an aging population, given that the prevalence
of atrial fibrillation7 and the incidence of venous throm-
boembolism8 both increase with age. 
The foremost complication of OAC therapy is the
development of major bleeding. In the phase III random-
ized clinical trials which compared warfarin and direct
OAC – namely dabigatran etexilate, rivaroxaban, apixa-
ban and edoxaban (DOAC hereafter) – in patients with
atrial fibrillation and venous thromboembolism, this risk
was reported to be 1-3% per year.9 In clinical practice
some studies have reported similar risks of major bleed-
ing,10-12 while others have found that it may be consider-
ably higher.13,14
When DOAC were first introduced into clinical practice
there was concern among clinicians that the lack of specif-
ic antidotes could be detrimental to patients’ outcomes in
the event of major bleeding. Recently, ‘post-approval’
observational studies have reported on the safety profile
of DOAC; however, these studies have primarily focused
on patients with atrial fibrillation, using patients’ clinical
data obtained from national registries/databases which
were designed for different purposes.15 Moreover, these
studies lacked detail on the acute management of the
bleeds. The burden (with respect to in-hospital mortality,
morbidity and duration of hospitalization) of major bleed-
ing associated with all OAC, for any clinical indications,
remains largely unknown. This dearth of knowledge is
true even in the case of warfarin, which has been the
mainstay of OAC therapy for more than 60 years.
Moreover, the widespread and increasing use of OAC,
particularly in the frail elderly, underscores the urgency of
comparative studies to assess the burden of major bleed-
ing events associated with warfarin and DOAC. Such
information should be incorporated into the clinical
assessment and counseling of patients prescribed OAC, as
well as the optimization of strategies for the management
of OAC-associated major bleeding events.
Major bleeding associated with oral anticoagulants
haematologica | 2018; 103(4) 739
Table 1. Baseline characteristics by type of oral anticoagulanta.
Total Warfarin Dabigatran Rivaroxaban Apixaban
number (%)
Total patients 2,192 (100) 1,771 (81) 46 (2) 283 (13) 89 (4)
Female 1,028 (47) 814 (46) 24 (52) 153 (54) 35 (39)
Age (years), median[IQR] 80 [72-86] 79 [71-85] 85 [79-88] 82 [74-88] 81 [76-86]
<65 284 (13) 246 (14) 2 (4) 29 (10) 7 (8)
65-74 408 (19) 348 (20) 6 (13) 42 (15) 12 (13)
75-84 863 (39) 714 (40) 12 (26) 96 (34) 39 (44)
≥85 637 (29) 463 (26) 26 (57) 116 (41) 31 (35)
Indicationsc
Atrial fibrillation 1,575 (72) 1,265 (71) 38 (83) 193 (68) 76 (85)
Venous thromboembolism 456 (21) 352 (20) 3 (7) 89 (31) 11(12)
Mechanical heart valve 212 (10) 211 (12) --- 1 (<1) ---
Other 184 (8) 143 (8) 11 (24) 18 (6) 12 (13)
Prescribed anti-thrombotics 
Single antiplatelet therapy 193 (9) 144 (8) 3 (7) 35 (12) 11 (13)
Dual antiplatelet therapy 27 (1) 23 (1) --- 1 (<1) 3 (3)
LMWH/UFH 53 (2) 47 (3) 1 (2) 5 (2) ---
Co-morbidities (type)
Congestive heart failure 342 (16) 278 (16) 4 (9) 46 (16) 14 (16)
Hypertension 1,181 (54) 949 (54) 28 (61) 154 (54) 50 (56)
Previous stroke/TIA 432 (20) 334 (19) 17 (37) 56 (20) 23 (26)
Liver failured 35 (2) 28 (2) 1 (2) 6 (2) ---
Cancer 334 (15) 258 (15) 6 (13) 55 (19) 14 (16)
Diabetes 494 (23) 402 (23) 9 (20) 62 (22) 21 (24)
Peripheral vascular disease 66 (3) 49 (3) 2 (4) 13 (5) 2 (2)
Ischemic heart disease 570 (26) 456 (26) 15 (33) 69 (24) 29 (33)
Chronic kidney diseased 339 (15) 282 (16) 2 (4) 49 (17) 6 (7)
Alcohol dependence 48 (2) 39 (2) 1 (2) 7 (2) 1 (1)
Dementia 144 (7) 97 (5) 2 (4) 35 (12) 8 (9)
Recurrent falls 128 (6) 94 (5) 4 (9) 24 (8) 6 (7)
Previous major bleeding
Intracranial hemorrhagee 81 (4) 64 (4) 2 (4) 11 (4) 4 (4)  
Gastrointestinal bleed 87 (4) 71 (4) 2 (4) 10 (4) 4 (4)
Other bleeds 38 (2) 29 (2) 3 (7) 6 (2) ---
Bleed history unknown 626 (29) 513 (29) 11 (24) 73 (26) 28 (31)
LMWH: low molecular weight heparin; UFH: unfractionated heparin; TIA: transient ischemic attack; aEdoxaban patients not shown separately (n=3). c10% of patients had more
than one indication. dSee appendix for definitions of liver and renal failure. eIncludes two with additional non-intracranial previous bleeds 
The main objectives of this study were to: (i) describe
the burden of major hemorrhage associated with all avail-
able OAC in terms of proportion of bleeds which are
intracranial, in-hospital case-fatality and morbidity, and
duration of hospitalization; (ii) identify risk factors for
fatality; (iii) compare characteristics of major hemorrhage
between patients treated with warfarin and DOAC for the
subgroups anticoagulated for atrial fibrillation or venous
thromboembolism,  the clinical conditions for which
DOAC are indicated.
Methods
Study design
The ORANGE (ORal ANticoagulant aGEnt-associated bleed-
ing events reporting system) study was a prospective cohort
study that collected information from multiple UK hospitals on
the presentation and clinical outcomes of patients who were
admitted for a major bleeding episode while on OAC therapy.
Ethics approval was obtained for the study from the National
Health Service, Health Research Authority (East of England-
L. Green et al.
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Table 2. Bleeding characteristics and outcomes.
Number (%)
Total patients 2,192 (100)
All intracranial hemorrhage 963 (44)
Subdural/epidural 386 (18)
Intracerebrala 474 (22)
Subarachnoidb 103 (5)
All gastrointestinal bleeds 712 (32)
UpperC 443 (20)
Lower 269 (12)
Other bleeds 517 (24)
Visceral 131 (6)
Genitourinary 87 (4)
Musculoskeletal 224 (10)
Miscellaneous (e.g. intra-ocular, puncture and surgical sites) 75 (4)
Provocation of bleeding
Spontaneous 1,434 (65)
Trauma (excluding fall) 200 (9)
Surgery or procedure 105 (5)
Fall 432 (20)
Unclassifiedd 21 (1)
Outcomes up to 30 days Days to event,
median[IQR]
Died in hospital 446  (20) 3 [1-8]
Discharged from hospital 1,413 (64) 7 [3-13]
Still inpatient at 30 days 273  (12)
Lost to follow-up
Transferred to other hospital 47  (2) 2 [1-8]
Not submitted 13  (1)
Case fatality by groups Followed-up, N Died (%)
Overall 2,132 446  (21)
Age, years
<65 274 25  (9)
65-74 400 62  (16)
75-84 840 197 (23)
85+ 618 162  (26)
Type of oral anticoagulant
Warfarin 1,719 358 (21)
Direct oral anticoagulant 413 88 (21)
Site of bleed
All intracranial 923 302 33)
All gastrointestinal 704 91  (13)
Other 505 53  11)
aIncludes 32 with additional bleeds in other sites. bIncludes 17 with additional subdural bleed. cIncludes 18 with additional lower gastrointestinal bleed. dReported as "unknown"
or "not available".
Cambridge South Research Ethics Committee, reference:
12/EE/0431). Data on major bleeding events were submitted by
multiple hospitals across England, Scotland, Wales and Northern
Ireland between October 1, 2013 and August 31, 2016. Patients
underwent the normal course of treatment as directed by their
clinicians and hospital protocols; at no point was their care
altered for the purpose of this study. 
Definition of major bleeding
The definition of major bleeding adopted was an augmented
version of the International Society on Thrombosis and
Haemostasis criteria.16 It was defined as bleeding requiring hospi-
talization and at least one of the following: (i) resulting in death;
(ii) transfusion of ≥2 units of red blood cells or a drop in hemoglo-
bin of ≥20 g/L; (iii) symptomatic bleeding in a critical area or
organ, such as intracranial, intraspinal, intra-ocular, retroperi-
toneal, intra-articular or pericardial, or intramuscular with com-
partment syndrome; (iv) transfusion of fresh-frozen plasma; (v)
administration of prothrombin complex concentrate, recombinant
activated factor VII, factor VIII inhibitor bypassing activity or fib-
rinogen concentrate. The rationale for appending (iv) and (v) was
to ensure that the routes for case identification were as compre-
hensive as possible.
Data collection
Any patient of 18 years or over on OAC therapy at the time
when they developed major bleeding was eligible for the study.
Cases were reported consecutively and identified by clinical and
research staff in participating hospitals from the emergency
department, transfusion laboratory, pharmacy (if they stored
hemostatic agents) and hematology doctors who were called to
give medical advice on the management of these patients. 
The study collected information on patients’ baseline character-
istics; type of OAC and indication(s), as well as co-morbidities and
clinical outcomes at 30 days, death, or discharge, whichever
occurred first. Further information on details of data
collection/verification, and justification for sample size are given
in the Online Supplementary Material. 
Statistical analysis 
The first bleeding episode of each individual patient was ana-
lyzed, with all DOAC grouped together for comparisons.
Associations between categorical variables were examined with a
chi-squared or Fisher exact test and Mann-Whitney U tests were
used for continuous variables (all two-sided at a 5% level of signif-
icance). Multinomial logit models were used to estimate the con-
ditional odds ratios for DOAC versuswarfarin on the site of bleed-
ing (versus a reference site), adjusting for age and bleeding provo-
cation. Risk factors for in-hospital 30-day mortality were investi-
gated using mixed-effects multivariable logistic regression to take
into account intra-hospital correlation, controlling for age, co-mor-
bidities, bleeding provocation and indications for OAC therapy.
All analyses were performed using STATA version 14 (StataCorp
LP, USA).
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Table 3. Comparison of warfarin and direct oral anticoagulants, for patients with atrial fibrillation and/or venous thromboembolism (n=1958).
Warfarin All DOAC P
number (%) or median[IQR]
Total patients 1,557 401
Age, years 80  [72-85] 82 [75-88] <0.001a
Number of co-morbiditiesd
None 227 (15) 57 (14)
1-2 868 (56) 216 (54) 0.724b
3-4 398 (26) 107 (27)
5+ 64 (4) 21 (5)
CHA2DS2-VASc score 3 [2-4] 3 [2-5] 0.1a
HAS-BLED scoree 2 [1-3] 2 [2-3] 0.1a
Sites of bleed
Lower gastrointestinal 166 (11) 75 (19)
Upper gastrointestinal 293 (19) 101 (25)
Subdural 313 (20) 42 (10) <0.001b
Subarachnoid 74 (5) 17 (4)
Intracerebral 342 (22) 92 (23)
Other 369 (24) 7 4 (18)
Patients followed-up 1512 393
In-hospital deaths within 30 days 322 (21) 84 (21) 0.973b  
Days in hospital before death 3 [1-8] 3 [1-10] 0.948a
Days in hospital for discharged patients 7 [3-13] 6 [3-11] 0.303a
Number of complications in hospital
None 1,184 (76) 308 (77) 
1 229 (15) 60 0.977c
2 62 (4) 17 (4)
3+ 37 (2) 8 (2)
DOAC: direct oral anticoagulants. aMann Whitney test; bchi-squared test; cFisher exact test; dco-morbidities as described in Table 1 e score does not include the labile International
Normalized Ratio.  
Results
Cases were identified and reported by 32 hospitals
across the UK, with the median number (inter-quartile
range, IQR) of cases reported per hospital being 44 (25 –
88), and the median (IQR) duration for completing a case
report (measured from the date of bleeding) being 38 (13-
87) days. Table 1 shows the demographics, OAC therapy
specifications and co-morbidities of 2,192 individual
patients reported with major bleeding between October
2013 and August 2016; 34 (1.6%) had more than one
episode during the study period (data not shown). All
patients fulfilled the International Society of Thrombosis
and Haemostasis criteria for major bleeding: 20% had a
fatal bleed; 62% were transfused with ≥2 units of red
blood cells or had a drop of ≥20g/L hemoglobin; and 86%
had symptomatic bleeding in a critical organ (overall, 67%
of patients met more than one criteria). At the time of the
bleed, the majority of patients were on warfarin (81%)
with the remainder being on a DOAC. Patients taking an
OAC for atrial fibrillation and venous thromboembolism
made up 72% and 21% of the cohort respectively;
approximately 10% had multiple indications. 
Bleeding presentations and outcomes are shown in
Table 2. All intracranial hemorrhages (subdural, subarach-
noid and intracerebral bleeds combined), gastrointestinal
bleeds (upper and lower) and other bleeds made up 44%,
32% and 24% of the total, respectively. Two-thirds of the
bleeds were reported as spontaneous and one-fifth as
resulting from a fall. Outcomes up to 30 days were report-
ed for 2,132 (97%) patients. The overall in-hospital mor-
tality rate was 20.9% (95% CI: 19.2% - 22.7%) but was
32.7% (95% CI: 29.7-35.9%) among patients with an
intracranial hemorrhage. Bleeding was mentioned as the
cause of death in 70% of cases, while in 22% it was not,
and in 8% the cause of death was unknown/ or referred to
the coroner. Patients discharged within 30 days of bleed-
ing stayed a median of 7 days in hospital. In-hospital com-
plications included admission to an Intensive Care Unit
(10%), ventilation or acute respiratory distress syndrome
(5%), hemorrhagic stroke (3%), cardiac arrest (2%), sepsis
or pneumonia (2%), thrombotic events (2%), and re-
bleeding (2%).
For the management of bleeding, patients on warfarin
were given any blood transfusion (31%), prothrombin
complex concentrate (78%) and vitamin K (74%); patients
on DOAC were given any blood transfusion (43%), pro-
thrombin complex concentrate (39%) and tranexamic acid
(28%). OAC therapy was resumed in 43% of survivors
while they were in hospital. The proportions of patients
(among survivors) who restarted OAC after a bleed varied
by site of bleed: intracranial hemorrhage (24%), gastroin-
testinal (46%), other (65%), as well as indication: atrial
fibrillation (36%), mechanical heart valves (86%), venous
thromboembolism (50%), other (42%). One–third of
patients on a DOAC were restarted on a different OAC,
as were approximately one-fifth of patients with intracra-
nial hemorrhage or venous thromboembolism. Out of 111
DOAC patients, 29 (26%) were switched to vitamin K
antagonists and out of 610 patients on warfarin, 42 (7%)
were switched to a DOAC. 
Comparison of the 1,958 (89%) patients who were on
OAC for atrial fibrillation and/or venous thromboem-
bolism (Table 3) showed that those admitted on DOAC
were significantly older than those on warfarin (P<0.001),
but there was no significant difference in the number of
L. Green et al.
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Table 4. Univariable and multivariable analysis of risk factors for mortality (n=2,132).
Univariable analysis Adjusted Multivariable analysis
OR [95%CI] P ORa [95%CI] P
Age (years)
<65 1 1
65-74 1.84 [1.12,3.01] 0.016 1.50 [0.89,2.53] 0.12
75-84 3.07 [1.97,4.80] <0.001 2.77 [1.73,4.44] <0.001
85+ 3.59 [2.28,5.65] <0.001 3.78 [2.33,6.14] <0.001
Type of oral anticoagulant
Warfarin 1 1
Direct oral anticoagulantb 0.99 [0.76, 1.31] 0.98 0.96 [0.71,1.28] 0.77
Site of bleed
Other 1 1
Lower gastrointestinal 0.65 [0.38, 1.12] 0.12 0.45 [0.25, 0.79] 0.005
Upper gastrointestinal 1.67 [1.14, 2.46] 0.01 1.17 [0.78, 1.75] 0.44
Subdural/epidural 2.43 [1.66, 3.55] <0.001 2.55 [1.69, 3.84] <0.001
Subarachnoid 2.72 [1.58, 4.68] <0.001 3.23 [1.82, 5.71] <0.001
Intracerebral 6.34 [4.51, 8.91] <0.001 5.75 [4.01, 8.23] <0.001
Provocationc
Spontaneous 1 1
Trauma 0.82 [0.55,1.21] 0.31 0.54 [0.35, 0.83] 0.005
Surgery/procedure 0.23 [0.10,0.52] 0.001 0.50 [0.21, 1.19] 0.12
Fall 0.97 [0.74,1.28] 0.84 0.53 [0.38, 0.73] 0.001
Liver failure 2.08 [1.02,4.26] 0.04 3.86 [1.79, 8.36] 0.001
Cancer 1.29 [0.97,1.70] 0.08 1.37 [1.01, 1.84] 0.04
OR: odds ratio; aOdds ratios adjusted for all other variables in model; bIncludes dabigatran, rivaroxaban, apixaban and edoxaban; cunclassified provocations not displayed (n=21).
co-morbidities between them. The type of OAC was
associated with the site of bleeding (P<0.001); after adjust-
ing for age and bleeding provocation using multinomial
models, the conditional odds ratios of admission with a
subdural/epidural, subarachnoid and intracerebral bleed
(versus a lower gastrointestinal bleed) on DOAC compared
to warfarin, were 0.28 (95% CI: 0.17-0.47; P<0.001), 0.52
(95% CI: 0.30-0.90; P=0.02) and 0.61 (95% CI: 0.41-0.92;
P=0.02), respectively. Mortality rate, the number of com-
plications following bleeding, and the duration of hospi-
talization were not significantly different between
patients treated with warfarin or DOAC. 
Table 4 shows the analysis of risk factors for fatality in
2,132 patients with known outcomes. After controlling for
age, co-morbidities, bleeding site and provocation, there
was no evidence that compared to warfarin, DOAC were
associated with different odds of death (adjusted
OR=0.96; 95% CI: 0.71-1.28; P=0.77). Intracerebral, sub-
arachnoid and subdural/epidural bleeds were associated
with 5.8 (95% CI: 4.0-8.2), 3.2 (95% CI: 1.8-5.7) and 2.6
(95% CI: 1.7-3.8) times higher odds of death, respectively,
compared with other bleeds. Adjusting for other covari-
ates, advanced age, spontaneous bleeding (compared to
trauma or falls), liver failure and cancer were significantly
associated with increased odds of dying, while indications
for OAC were not predictors of an adverse outcome.
There was negligible between-hospital variation (intra-
class correlation coefficient=0.003). Given the relatively
small number of patients for whom outcome was missing
(n=60), sensitivity analyses were performed by assuming
either all survived or died, and this did not materially alter
the significance of the estimates.
Discussion 
The main objective of this study was to investigate the
aggregate burden of major hemorrhage in patients receiv-
ing OAC, across all indications and drug types, in terms of
ensuing mortality, morbidity and hospitalization. Our
results showed a considerable death rate, with one-fifth of
all patients, and one-third of those with intracranial hem-
orrhage, dying in hospital within 30 days of a major bleed-
ing episode. Of those who were discharged within a
month, half had spent 7-30 days in hospital. Our mortality
rates, both overall and for the subgroup with intracranial
hemorrhage, are comparable with those of other stud-
ies.17,18 However, a recent Canadian study that used a sim-
ilar definition of major bleeding as ours (including only
patients >66 years) showed lower mortality rates than in
our study (9.2% for DOAC and 15.2% for warfarin): this
difference is likely to be due to the lower rate of intracra-
nial hemorrhage (27% overall) seen in their study.19
The proportion of patients with intracranial hemor-
rhage (44%) was similar to that in the study by Becattini
and colleagues,20 but higher than that in other studies.19,21
The higher rate may be due to: (i) one-third of our cases
being from hospitals with specialist neurosurgical units
(i.e. endpoints of inter-hospital referrals); (ii) our cohort
including patients who were older than those in clinical
trials and thus more prone to falls and the development of
intracranial hemorrhage; (iii) our definition of major bleed-
ing being more severe than those of clinical trials, as we
identified only patients who developed major hemorrhage
culminating in hospitalization; (iv) cases of intracranial
hemorrhage being more exhaustively documented (e.g.
through administration of prothrombin complex concen-
trates), compared with gastrointestinal or other bleeds.
The pivotal randomized controlled trials of patients
with atrial fibrillation and venous thromboembolism
found lower rates of intracranial hemorrhage with all
DOAC than with warfarin, and higher rates of gastroin-
testinal bleeding with dabigatran and rivaroxaban than
with warfarin.9,21 A systematic review of randomized clin-
ical trials by Connolly and colleagues22 concluded that “the
risks of subdural hematoma were significantly higher with
vitamin K antagonists compared with factor-Xa inhibitors
and direct thrombin inhibitors” [meta-analysis odds ratio
(95% CI): 2.9 (2.1–4.1) and 1.8 (1.2–2.7), respectively]. Our
findings appear to be a corollary of the established evi-
dence: while our study did not directly assess the inci-
dence of bleeding on OAC, we observed increased odds of
admission with all types of intracranial hemorrhage versus
gastrointestinal bleeding on warfarin compared to DOAC,
with the association being strongest for subdural/epidural
bleeding. Further investigation into this association
between warfarin and subdural hematoma would thus be
an important topic in future research.  
Analysis of risk factors for death showed that intracra-
nial hemorrhage was a strong predictor of death.
However, we saw no difference in the proportions of
deaths between patients treated with warfarin or DOAC
even though the proportion of intracranial hemorrhage
was higher for the former. A likely explanation for this is
that patients admitted on DOAC were significantly older
than those on warfarin, and advanced age was also an
independent risk factor for death. The participants in the
clinical trials of warfarin versus DOAC were significantly
younger than those in our study. However, our results pro-
vide reassurance for clinicians who prescribe DOAC ther-
apy in that, where major bleeding is concerned, the out-
come is no worse than that associated with warfarin
despite the lack of antidotes and the advanced age of
many patients in this study. Since DOAC antidotes are
now becoming available it is important to perform similar
studies to assess the effect that these have on outcomes,
and thereby improve OAC choices in the future. 
A key strength of this study is that the data were
prospectively collected by over 30 hospitals across the UK,
with information retrieved directly from patients’ case
notes and not from large databases in which data are col-
lected for different reasons, or missed by administrative
coding.23-26 This has enabled us to document for the first
time in the UK the characteristics and clinical outcomes of
patients who develop major bleeding associated with dif-
ferent OAC when prescribed for any clinical indications.
Additionally, over three-quarters of cases were fully
reported within 90 days of the major bleeding episode,
ensuring a high degree of fidelity with actual events and
minimizing the chance of recall bias. Furthermore, we
were able to collect data on the acute management of
major bleeding, whereas this is not usually possible from
large data sets. Our analysis showed a very low level of
inter-hospital variation, which suggests that our findings
should be generalizable to the wider population and
potentially further afield. Moreover, the design of the
study meant that we did not rely on patients’ consent, a
further potential source of selection bias.
Our study also provides data on the outcomes of major
bleeding that are more generalizable to contemporary
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practice than those observed in the randomized clinical
trials. Patients in the latter were more highly selected, and
the management of major bleeding in the trials appears
different from current recommended practice; for exam-
ple, among those with major bleeding in the open-label
warfarin arm of the RELY trial only 27% received vitamin
K and 1% received a prothrombin complex concentrate27
in contrast to over 70% for both in our study.  
We identified patients who developed major bleeding
on OAC and were admitted to hospital, but it is possible
that not every case was captured, because they were not
triaged to emergency departments, and thus could have
been missed by the research team. The upshot is that we
may have collected data on the more severe bleeding cases
with consequently worse outcomes, although we expect
the numbers affected to be relatively small. Furthermore,
it could be argued that warfarin cases would have been
easier to capture through the prescription of prothrombin
complex concentrate. However, the methods of case iden-
tification were designed to capture all cases of major
bleeding from hospitals, independently of the type of
OAC, but we recognize that some cases could have been
inadvertently missed. 
It is also possible that we may have missed some cases
of fatal bleeding who died suddenly in the community;
however, we think these numbers will likely be small
because the majority would be taken to their local emer-
gency department because of acute deterioration.
Furthermore, we might have missed the outcome of
patients who were discharged before 30 days; however, it
seems a reasonable stipulation that patients were dis-
charged from hospital if and when major bleeding had
been successfully treated or resolved, and hence restricting
follow-up to within the hospital is justifiable on the
grounds that any post-discharge deaths would not be “fol-
lowing from the bleeding event”.  
In conclusion, for clinicians who are responsible for
counseling patients about oral anticoagulation our find-
ings indicate that mortality from major bleeding on OAC
that requires hospitalization is high, with one in five
patients likely to die within 30 days. This is of concern
given the widening use of these agents in an increasingly
elderly and frail population. As far as DOAC are con-
cerned, our results provide reassurance, in that they are
not associated with worse outcomes compared to war-
farin despite the lack of antidotes at the time of the study.
As the DOAC antidotes emerge, it would be important for
future studies to investigate their impact on patients’ out-
comes compared to current practice. 
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